Hunting Hill Global Capital’s Royalty Pharma RPRX Stock Holding History

Hunting Hill Global Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,036	Closed	-$290K	–	54
2026 Q1	$290K	Sell	6,036 -6,604	-52%	-$289K	0.22%	60
2025 Q4	$488K	Sell	12,640 -3,294	-21%	-$126K	0.34%	55
2025 Q3	$562K	Hold	15,934	–	–	0.16%	63
2025 Q2	$574K	Hold	15,934	–	–	0.16%	69
2025 Q1	$496K	Hold	15,934	–	–	0.3%	59
2024 Q4	$406K	Hold	15,934	–	–	0.15%	62
2024 Q3	$451K	Hold	15,934	–	–	0.43%	46
2024 Q2	$420K	Hold	15,934	–	–	0.19%	71
2024 Q1	$484K	Buy	+15,934	New	+$470K	0.24%	74

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hunting Hill Global Capital's RPRX Position: Q2 2026 in Review

Hunting Hill Global Capital sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 6,036 shares — an estimated $290K sold.

Hunting Hill Global Capital first reported a position in RPRX in Q1 2024 and held it in 9 quarters. The position peaked at $574K in Q2 2025. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Hunting Hill Global Capital reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
Hunting Hill Global Capital sold 6,036 Royalty Pharma shares in Q2 2026, an estimated $290K.
Hunting Hill Global Capital first reported a position in Royalty Pharma in Q1 2024 and held it in 9 quarters.
Hunting Hill Global Capital's Royalty Pharma position peaked at $574K in Q2 2025.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Hunting Hill Global Capital's 13F filing for Q2 2026.